On August 18, BEONE MEDICINES rose 3.08% in regular trading, trading at 219.4 HKD/share, with turnover of approximately 90.96 million HKD.

On the news front, JPMorgan Chase purchased 4.1197 million shares of BEONE MEDICINES on August 11 at an average price of 219.79 HKD per share, investing approximately 905 million HKD and raising its stake from 8.77% to 9.05%. The company's audit committee is scheduled to review interim results for the six months ended June 30 on August 26. The company previously disclosed H1 revenue of 22.22 billion yuan, up 26.8% year-over-year, and net profit attributable to shareholders of 3.271 billion yuan, surging 627.1% year-over-year.

Multiple institutions recently raised target prices, with CLSA upgrading to 321.7 HKD, BOCOM International to 276 HKD, and CICC maintaining 266 HKD, all assigning buy or outperform ratings. The strong institutional buying and upcoming results review have collectively bolstered market sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)